Freemelt (FREEM) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
11 Aug, 2026Executive summary
Record order intake of 22.2 million SEK in Q2, up 11% year-over-year, with a stable order book at 25.6 million SEK.
Net sales reached 9.039 million SEK, down 53% compared to the previous year, mainly due to timing of machine deliveries.
Strategic progress in MedTech, defense, and fusion segments, including new orders and alliances in the U.S., Europe, and China.
SEK 35 million was raised through warrant subscription, with 97% of outstanding warrants exercised, bolstering financial stability.
Expansion of manufacturing capabilities for extreme materials like tungsten, with new leadership roles and funding partnerships.
Financial highlights
Gross margin was strong at 60% in Q2, driven by a favorable sales mix and high-margin aftermarket and secondhand sales.
Operating result for Q2 was SEK -23,370k; result after financial items was SEK -23,425k.
Operating expenses decreased to 37.5 million SEK, down from 46.8 million SEK year-over-year.
Cash at bank stood at 41.6 million SEK at the end of June, supported by warrant exercise proceeds.
Cash flow for the period was SEK 14,132k, a significant improvement from SEK -17,814k in Q2 2025, mainly due to warrant conversion proceeds.
Outlook and guidance
Majority of the 25.6 million SEK order backlog expected to be recognized as revenue in the second half of the year.
High activity in customer projects and a strong orderbook position the company for continued growth in the second half of 2026.
Strategic focus remains on expanding the industrial platform for advanced metal components and leveraging partnerships in Europe, the US, and China.
Lead time from order to revenue recognition for machines is typically three to four months.
Cash burn and liquidity needs will be managed through expanded debt financing if growth continues.
Latest events from Freemelt
- Record sales, fusion breakthroughs, and China entry drive growth in AM and medtech.FREEM
Investor Update - Scaling up with 162% revenue growth, new funding, and global expansion in MedTech, defense, and fusion.FREEM
Investor update - Q1 net sales rose 116% YoY, with strong margins and key sector collaborations advancing.FREEM
Q1 2026 - Sales up 172% to SEK 54.5m, installed base up 40%, and strong growth in key sectors.FREEM
Q4 2025 - Record Q2 sales and global expansion drive strong growth and order intake.FREEM
Q2 2025 - Industrial 3D printing momentum grows, targeting SEK 1 billion sales by 2030.FREEM
ABGSC Investor Days - Q2 saw high activity, new orders, and strategic partnerships despite a wider loss.FREEM
Q2 2024 - First industrial eMELT sale, OEM order, and machine sales growth amid ongoing losses.FREEM
Q3 2024 - Strong Q4 growth, major orders, and capital raise drive expansion in core sectors.FREEM
Q4 2024